Clinical Trial Update: Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM [Phase 1]

View source ↗

Summary

Phase I trial evaluating the combination of bortezomib (Velcade) and pralatrexate in relapsed/refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Folotyn (pralatrexate)
• Velcade (bortezomib)

Snippet

Sponsor: Stanford University | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED